Although several anti-angiogenic therapies have been established, they have failed to improve survival outcomes in advanced cancers10,11, and their use has been associated with significant nephrotoxicity9,22, hypertension, and proteinuria because of a decrease in the production of vasoactive intermediates that occurs when VEGFA activity is inhibited, which in turn leads to vasoconstriction23. The gene discussed is VEGFA; the disease is Hypertension.